Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2025

Summary of Significant Accounting Policies

Reconciliation of income attributable to common stockholders for basic and diluted net income common per share

The following is a reconciliation of the Company’s income attributable to common stockholders for basic and diluted net income per common share (in thousands):


		Three Months Ended March 31,
		2024			2025
Net income attributable to Antero Resources Corporation—common shareholders		$	22,730			207,971
Add: Interest expense for 2026 Convertible Notes			256			—
Less: Tax-effect of interest expense for 2026 Convertible Notes			(56)			—
Net income attributable to Antero Resources Corporation—common shareholders and assumed conversions		$	22,930			207,971

Net income per common share—basic		$	0.07			0.67
Net income per common share—diluted		$	0.07			0.66

Weighted average common shares outstanding—basic			304,943			311,328
Weighted average common shares outstanding—diluted			312,503			314,798

Reconciliation of basic weighted average shares outstanding to diluted weighted average shares outstanding

The following is a reconciliation of the Company’s basic weighted average common shares outstanding to diluted weighted average common shares outstanding during the periods presented (in thousands):


		Three Months Ended March 31,
		2024		2025
Basic weighted average number of common shares outstanding		304,943		311,328
Add: Dilutive effect of RSUs		1,307		1,689
Add: Dilutive effect of PSUs		1,389		1,781
Add: Dilutive effect of 2026 Convertible Notes		4,864		—
Diluted weighted average number of common shares outstanding		312,503		314,798

Weighted average number of outstanding securities excluded from calculation of diluted net income per common share ⁽¹⁾:
RSUs		371		—
Stock options		259		252

(1)	The potential dilutive effects of these securities were excluded from the computation of net income per common share—diluted because the inclusion of these securities would have been anti-dilutive.